The launch of Prizvalve Pro holds profound significance for the field of interventional cardiac valve treatment in China. On one hand, it breaks the long-term monopoly of foreign similar products in the high-end market, achieving the goal of domestic substitution of innovative medical devices, and providing Chinese medical institutions with more high-quality, cost-effective options, allowing the benefits of innovative healthcare to reach a broader population. On the other hand, as an advanced medical device independently developed in China, it demonstrates the country's strength in the field of high-end medical equipment manufacturing, encouraging more domestic companies to increase R&D investment, promote technological upgrades in related industries, and drive China’s medical industry toward higher levels, contributing to the realization of the Healthy China strategic goals.

NewMed stated that, in the future, it will continue to uphold the mission of "Innovation Benefits Life," constantly optimize product performance, expand the scope of clinical applications, while strengthening cooperation with medical institutions and research academies. It aims to promote the popularization and development of heart valve interventional treatment technology, build a value loop of "technological breakthrough - clinical application - patient benefits," and allow more patients to benefit from the medical advancements brought by technological innovation.